Organon Financial Ratios
NYSE: OGNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Organon ratio analysis
Organon earned a net margin of 3.0% in FY 2025, down from 13.5% a year earlier. Gross margin was 53.3% compared with a median of 62.5% over the prior 6 years. Return on equity reached 24.9%, meaning Organon generated 0.25 dollars of profit for every dollar of shareholders' equity.
Debt-to-equity stood at 11.49 versus 18.81 the year before, and the current ratio was 1.82. At the end of FY 2025, OGN traded at 10.1 times earnings; across the 5 fiscal years shown, its year-end P/E ranged from 3.6 to 10.1, with a median of 5.7. Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
Organon financial ratios (annual)
| Ratio | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| P/E ratio (at fiscal year end) | 10.06 | 4.64 | 3.61 | 7.78 | 5.73 | — | — |
| Price / sales | 0.30 | 0.62 | 0.59 | 1.15 | 1.22 | — | — |
| Price / book | 2.50 | 8.41 | — | — | — | — | — |
| Gross margin | 53.3% | 58.0% | 59.8% | 62.8% | 62.2% | 67.6% | 70.8% |
| Net margin | 3.0% | 13.5% | 16.3% | 14.9% | 21.4% | 33.1% | 41.4% |
| Free cash flow margin | 8.7% | 11.9% | 8.7% | 10.7% | 31.2% | 31.1% | 37.6% |
| Return on equity (ROE) | 24.9% | 183.1% | — | — | — | 39.4% | 45.7% |
| Return on assets (ROA) | 1.5% | 6.6% | 8.5% | 8.4% | 12.6% | 21.4% | — |
| Debt / equity | 11.49 | 18.81 | — | — | — | 0.00 | — |
| Current ratio | 1.82 | 1.60 | 1.54 | 1.56 | 1.45 | 1.33 | — |
| Revenue growth | -2.9% | 2.2% | 1.4% | -2.1% | -3.5% | -16.0% | — |
| EPS growth | -78.4% | -16.5% | 11.1% | -32.4% | -37.7% | -32.9% | — |